Trial Profile
A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs RX 5902 (Primary)
- Indications Advanced breast cancer; Ovarian cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Rexahn Pharmaceuticals
- 03 Jan 2020 Status changed from active, no longer recruiting to discontinued.
- 09 Sep 2019 Planned End Date changed from 1 Jan 2019 to 1 Nov 2019.
- 09 Sep 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Oct 2019.